Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Wolfspeed Sues Navitas Over GaN and SiC Patent Infringement 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Oil and LNG Tankers Turn Back as Strait of Hormuz Security Risks Escalate 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
Bain Capital Exits Kioxia After AI-Fueled Valuation Surge 
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy 
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Fast Retailing Raises Full-Year Forecast After Uniqlo Owner Beats Q3 Profit Estimates 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
Zhipu AI Stock Jumps on Report of Custom AI Chip Development Plans 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Irvine, CA, May 03, 2018 -- TRIMEDYNE, INC. (OTCPINK “TMED”) today reported its financial results for its quarter ending on March 31, 2018.
For the quarter ended March 31, 2018, Trimedyne had revenues of $1,352,000, an increase of 21% from revenues of $1,119,000 for the prior year quarter. We had a net income for the current quarter of $24,000 or $0.20 per share, as compared to a net loss of $31,000 or $(0.25) per share for the prior year quarter. The net income during the current quarter as compared to a net loss during the prior year quarter is a considerable improvement, which was primarily the result of an increase of export sales revenue and the continuation of our cost controls.
For the six-month period ended March 31, 2018, Trimedyne had revenues of $2,886,000, an increase of 30% from revenues of $2,213,000 for the prior year six-month period. We had net income for the current six-month period of $110,000 or $0.90 per share, as compared to a net loss of $256,000 or $(2.09) per share for the prior year six-month period. The net income during the current six-month period as compared to a net loss during the prior year six-month period is a considerable improvement, which was primarily the result of an increase of export sales revenue and the continuation of our cost controls.
Commenting on the financial results for the quarter, Marvin P. Loeb, Sc.D., Chairman of Trimedyne, said: “Since we are no longer required to file periodic reports with the SEC, our Financial Statements are un-audited. However, we believe our Financial Statements have been prepared and contain all adjustments of a recurring nature that are necessary for a fair presentation of our operations and financial condition for the periods and dates shown.”
“We appreciate the patience of our shareholders, and we are working hard to improve our financial condition.”
If you would like a copy of the financial statements, please send an email to [email protected], and we will be happy to send it to you.
CONTACT: Jeffrey Rudner (949) 951-3800, Ext. 285 [email protected]
